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Introduction 
Lobar atelectasis occurs in 411% of patients 
with cystic fibrosis (CF) (1,2). A large proportion 
of these do not resolve despite intensive medical 
treatment. A 31-year-old patient with CF developed 
a right upper lobe atelectasis which was resistant 
to conventional medical treatment. Two months later 
he was started on recombinant human DNase I 
(rhDNase) which was associated with partial resol- 
ution of the atelectasis and reduction in sputum 
viscoelasticity. 
Case Report 
A 31-year-old male with CF who suffered from 
recurrent respiratory infections presented with 
increased sputum production, dyspnoea, night 
sweats and fevers. He produced approximately 
50 ml of thick tenacious sputum daily. His lung 
spirometry was forced vital capacity (FVC) of 
2.45 1, and forced expiratory volume in one second 
(FEV,) of 1.1 1. Chest radiograph showed right 
upper lobe collapse, cystic changes and ring shad- 
ows of bronchiectasis. There was no blood eosino- 
philia, aspergillus precipitins were negative and full 
viral, mycoplasma and legionella infection screens 
were negative. Sputum culture grew mucoid 
Pseudomonas aeruginosa. Intravenous antibiotics, 
systemic bronchodilators, steroids and intensive 
physiotherapy were administered. The patient 
received a combination of intravenous antibiotics 
which included azlocillin, ceftazidime, imipenem, 
and aminoglycosides for a total of 31 days. In 
addition he continued on his prophylactic nebulized 
antibiotics. Physiotherapy consisted of postural 
drainage and active cycle of breathing exercises 
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including the forced expiratory technique. This was 
augmented with nebulized hypertonic saline and 
intermittent positive pressure breathing with the 
Bird ventilator for a period of 27 days. The patient 
also underwent bronchoscopy. Thick sputum plugs 
were aspirated by a very experienced bronchosco- 
pist, no endobronchial lesion was seen but the chest 
radiograph following the procedure remained 
unchanged. Failure of medical treatment prompted 
a second bronchoscopy. Fewer secretions were seen 
on this occasion but the right upper lobe failed to 
re-expand. 
Two months later the patient was treated with 
rhDNase 2.5 mg nebulized twice daily as part of a 
clinical trial. Chest radiograph prior to commencing 
rhDNase still showed the right upper lobe collapse 
[Plate l(a)]. His FVC was 3.06 1 and FEV, 1.13 1. He 
did not receive intravenous antibiotics or intensive 
physiotherapy 15 days prior to commencement on 
rhDNase. After about 2 weeks of treatment the 
patient started producing copious amounts of spu- 
tum (approximately 15&200 ml daily). He developed 
chest pain on the anterior aspect of the right side of 
his chest and was more breathless. Spirometry on day 
14 of treatment with rhDNase was FVC 3.28 1 and 
FEV, 1.12 1. Sputum production started to decrease 
and on day 28 a repeat chest radiograph showed 
partial re-expansion of the right upper lobe [Plate 
l(b)l. 
Fresh sputum samples were obtained on presenta- 
tion, pre-treatment with rhDNase and on day 28 of 
treatment with rhDNase and stored at - 20°C. The 
dynamic storage modulus (G’), which reflects the 
elasticity of the sample, and the dynamic loss modu- 
lus (G”), which is related to viscosity of the sputum 
samples was measured using oscillatory analysis on a 
parallel plate rheometer (CSL 100, Carri-Med UK) 
(3,4). Viscoelasticity was similar for the samples 
obtained at presentation and after conventional 
treatment but significantly reduced after treatment 
with rhDNase (Fig. 1). 
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Chest radiograph prior to treatment with rhDNase showing right upper lobe collapse (a) and post treatment 
\Jase for 28 days showing resolution of right upper lobe collapse (b). 
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Fig. I Dynamic elasticity (a) and dynamic viscosity (b) of 
sputum samples obtained at (m) presentation, (+) pre- 
treatment with rhDNase, and ( X ) on day 28 of treatment 
with rhDNase. A significant reduction of sputum elasticity 
(P<O.OOOl) and sputum viscosity (P<O4001) occurred fol- 
lowing treatment with rhDNase compared to pre-treatment. 
with 
Discussion 
Lobar atelectasis is a well documented com- 
plication of CF. The pathophysiology may be a 
combination of bacterial infection and the presence 
of endobronchial obstruction with a thick viscous 
exudate. Conventional medical treatment consists of 
antimicrobial therapy and vigorous pulmonary phys- 
iotherapy. Intermittent positive pressure breathing 
and nebulized hypertonic saline has been used to 
facilitate sputum expectoration (5). Bronchoscopy 
has been utilized for both diagnostic and therapeutic 
purposes. Unfortunately in this patient the above 
treatments had little effect. 
The high sputum viscosity found in patients with 
CF has been attributed to the presence of deoxyribo- 
nucleic acid (DNA). The DNA is derived almost 
entirely from disintegrated neutrophils (6,7,8). RhD- 
Nase has been shown to reduce the viscosity of CF 
sputum in vitro by depolymerizing DNA (9). 
In our patient treatment with rhDNase resulted in 
a remarkable reduction of sputum viscosity. Follow- 
ing sufficient treatment the persistent endobronchial 
obstruction due to thick tenacious secretions was 
relieved. This was reflected in the partial resolution of 
the right upper lobe atelectasis. 
Lobar atelectasis in CF is difficult to treat and in 
some patients may progress to severe irreversible 
bronchiectasis. Some individuals may even require 
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a lobectomy. RhDNase reduces viscoelasticity of 
secretions in CF and may in particular significantly 
improve the treatment of CF patients with lobar 
atelectasis. 
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